Anónimo. Ginkgo biloba: to be avoided due to severe adverse effects. Prescrire Int 2019;28:155-6. [Ref.ID 103129]

Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ 2018;360:k714. [Ref.ID 102544]

Montastruc J-L. A propos du Levothyrox® : les réflexions du pharmacologue médical. BIP31.fr 2017;24:60. [Ref.ID 102182]

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

Anónimo. Oxyhydroxyde sucroferrique et patients dialysés. Prescrire 2017;37:96-7. [Ref.ID 101439]

Anónimo. Maladie de Basedow chez les adultes. Prescrire 2016;36:833-40. [Ref.ID 100952]

Anónimo. Diarrhées d'origine médicamenteuse. Prescrire 2016;36:748-55. [Ref.ID 100894]

Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]

Anónimo. Drugs for hypothyroidism. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:147-50. [Ref.ID 99814]

Warlé-van Herwaarden MF, Valkhoff VE, Herings RMC, Engelkes M, van Blijderveen JC, Rodenburg EM, de Bie S, Alsma J, van de Steeg-Gompel C, Kramers C, Meyboom RHB, Sturkenboom MCJM, De Smet PAGM. Quick assessment of drug-related admissions over time (QUADRAT study). Pharmacoepidemiol Drug Saf 2015;24:495-503. [Ref.ID 98885]

Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab 2014;99:4481-6. [Ref.ID 98392]

Anónimo. Sucroferric oxyhydroxide (Velphoro) for hyperphosphatemia. Drug Ther Bull 2014;56:76-7. [Ref.ID 98173]

Razvi S, Weaver JU, Butler TJ, Pearce SHS. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med 2012;172:811-23. [Ref.ID 93055]

Collet T-H, Gussekloo J, Bauer DC, den Elzen WPJ, Cappola AR, Balmer P, Iervasi G, Asvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RMB, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Comuz J, Newman AB, Khaw K-T, Westendorp RGJ, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N, for the Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012;172:799-809. [Ref.ID 93054]

Montastruc J-L. Médicaments déterminant HTA : du nouveau !. BIP31.fr 2012;19:19-20. [Ref.ID 92664]

Bell CM, Brener SS, Gunraj N, Huo C, Bierman AS, Scales DC, Bajcar J, Zwarenstein M. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases . JAMA 2011;306:840-7. [Ref.ID 91011]

Turner MR, Camacho X, Fischer HD, Austin PC, Anderson GM, Rochon PA, Lipscombe LL. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ 2011;342:1011. [Ref.ID 90792]

Leese GP, Flynn RV. Levothyroxine dose and fractures in older adults. BMJ 2011;342:986-7. [Ref.ID 90785]

Anónimo. Interrupción perioperatoria de la medicación crónica. Boletín Terapéutico Andaluz 2010;26:9-12. [Ref.ID 89835]

Bolk N, Viser TJ, Nijman J, Jongste IJ, Tijssen JGP, Berghout A. Effects of evening vs morning levothyroxine intake. A randomized double-blind crossover trial. Arch Intern Med 2010;170:1996-2003. [Ref.ID 89785]